E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
Northwest Biotherapeutics, Inc. New Common stock  
Northwest Biotherapeutics, Inc. New Common stock
NWBOLast: $0.99 ($+0.01)Volume: 314,549Last Trade: 8/5/2010 5:20:15 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
OTCBB:NWBO $0.99 ($+0.01 +1.0204%)
Industry: Health Sector: Pharmaceuticals
Open: 1.04 Previous Close: 0.98
Day's High: 1.13 Day's Low: 0.961
52-Week High: 7.33 52-Week Low: 1.05
 
Bid: 0.95 / 2,500 Ask: 1.03 / 500
Volume: 314,549 Outstanding: 0
Market Cap: -
Northwest Biotherapeutics, Inc. New Common stock Profile
Northwest Biotherapeutics is a development stage biotechnology company that focuses on discovering, developing and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer. Co.'s approach in developing cancer therapies utilizes its knowledge in the biology of dendritic cells, which are a type of white blood cells that activate the immune system. Co. has two basic technology platforms applicable to cancer therapeutics: dendritic cell-based cancer vaccines, which it calls DCVax, and monoclonal antibodies for cancer therapeutics. The DCVax dendritic cell-based cancer vaccine program is Co.'s main technology platform.
 Northwest Biotherapeutics, Inc. New Common stock News & Press Releases

Long-Term Follow-Up of DCVax®-Treated Brain Cancer Patients Shows 33% of Patients Reached 4-Year Sur
BETHESDA, Md. , Aug. 3 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") ( NWBO ) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical tri... [more]

Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
BETHESDA, M.D., July 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") ( NWBO ), developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding... [more]

Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record
BETHESDA, Md. , Feb. 8 /PRNewswire/ -- Northwest Biotherapeutics, Inc. ( NWBO ), a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Ma... [more]

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Strikin
BETHESDA, Md. , Feb. 17 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS) ("NWBT" or the "Company") today announced further long-term follow-up da... [more]

Northwest Biotherapeutics Secures $700,000 Equity Financing
BETHESDA, Md. , Feb. 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBS and NWBT; NWBO ) (the "Company") announces today receipt of $700,000 in cash... [more]

Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Actio
BETHESDA, Md. , Jan. 8 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT) (the "Company" or "NWBT") announced today settlement of a putative securities... [more]

Northwest Secures US$0.5 Million Debt Financing
BETHESDA, Md. , Dec. 23 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT), today announced that it has obtained US$0.5 million in deb... [more]

Northwest Secures US$1.65 Million Debt Financing
BETHESDA, Md. , Nov. 6 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBS and NWBT), today announced that it has obtained US$1.65 million in fun... [more]

Northwest Secures US$1.0 Million Debt Financing
BETHESDA, Md. , Oct. 2 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS), today announced that it has entered into a Loan Agreement and Promissory... [more]

Long-Term Phase I and Phase I/II Trial Data Continue to Show Striking Improvement in Survival of Bra
BETHESDA, Md. , Sept. 11 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBO ; NWBT and NWBS) ("NWBT" or the "Company") today announced the most recent long-term fol... [more]

Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
BETHESDA, Md. , July 18 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ( NWBS and NWBT; NWBO ), (the "Company or NWBT"), today announced that Dr. Alton L. Boynto... [more]

Northwest Secures US$4.0 Million in Debt Financing
BETHESDA, Md., May 9 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. NWBO , today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in... [more]


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts